<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01667484</url>
  </required_header>
  <id_info>
    <org_study_id>102774</org_study_id>
    <nct_id>NCT01667484</nct_id>
  </id_info>
  <brief_title>Adderall XR and Processing Speed in Multiple Sclerosis (MS)</brief_title>
  <official_title>Does Adderall XR Improve Processing Speed in Cognitively Impaired MS Patients?</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>London Health Sciences Centre</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>London Health Sciences Centre</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Cognitive impairment, or problems with thinking and memory, is common in multiple sclerosis&#xD;
      (MS) and can occur independently of physical disability. It is the most common reason, along&#xD;
      with physical fatigue, for MS patients to stop working. The most frequent complaint is&#xD;
      problems with multi-tasking or thinking quickly, which corresponds to impairment in the&#xD;
      cognitive domain of processing speed. Currently there is treatment available to prevent&#xD;
      relapses and physical disability but there are no medications that have been shown to treat&#xD;
      cognitive impairment. Amphetamines have been beneficial for selective attention and&#xD;
      processing speed in attention deficit hyperactivity disorder (ADHD) and traumatic brain&#xD;
      injury. This is study will determine whether Adderall XR improves objective measures of&#xD;
      processing speed and attention in MS patients impaired in this cognitive domain, by comparing&#xD;
      two doses of Adderall XR (5 and 10mg) to placebo before and after the medication is&#xD;
      administered. The results of this study will help provide data to design a larger study to&#xD;
      determine if Adderall XR, and potentially other amphetamine drugs, will help treat cognitive&#xD;
      impairment in MS patients.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>September 2012</start_date>
  <completion_date type="Actual">February 2015</completion_date>
  <primary_completion_date type="Actual">February 2013</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in score of Paced Auditory Serial Addition Test (PASAT)</measure>
    <time_frame>pre and 7 hours post dose</time_frame>
    <description>measure of processing speed</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in Score of Symbol Digit Modalities Test (SDMT)</measure>
    <time_frame>pre and 7 hours post dose</time_frame>
    <description>measure of processing speed</description>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">70</enrollment>
  <condition>Impaired Processing Speed</condition>
  <condition>Cognitive Impairment</condition>
  <condition>Multiple Sclerosis</condition>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>treatment group #1</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Adderall XR 5mg</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>treatment group #2</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Adderal XR 10mg</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>treatment group #3</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Adderall XR 5mg</intervention_name>
    <arm_group_label>Adderall XR 5mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Adderall XR 10 mg</intervention_name>
    <arm_group_label>Adderal XR 10mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  - Males/Females who are ≥ 18 years old and ≤ 59 years old&#xD;
&#xD;
          -  Relapsing Remitting, Secondary Progressive or Primary Progressive MS, as per revised&#xD;
             McDonald's Criteria&#xD;
&#xD;
          -  Have not received corticosteroids in last thirty days or a relapse in the last ninety&#xD;
             days&#xD;
&#xD;
          -  An Expanded Disability Status Scale (EDSS) of ≤ 6.5&#xD;
&#xD;
          -  If female, must neither be pregnant nor breast-feeding&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  - Have evidence of other medical cause(s) of cognitive impairment&#xD;
&#xD;
          -  Have evidence of major depression as determined by a positive Beck Depression&#xD;
             Index-Fast screen ≥ 13and/or by clinician interview or evidence of severe fatigue with&#xD;
             a Fatigue Severity Scale ≥ 5.&#xD;
&#xD;
          -  Have demonstrated a hypersensitivity to amphetamines in the past&#xD;
&#xD;
          -  Have uncontrolled or labile hypertension (&gt; 135/85 mm Hg, treated or untreated)&#xD;
&#xD;
          -  Have a history of structural heart disease, including atherosclerosis or angina&#xD;
&#xD;
          -  Have a diagnosis of bipolar disorder or a history of a psychotic episode&#xD;
&#xD;
          -  The following medications are not permitted to be used within 14 days the study&#xD;
&#xD;
               1. Monoamine Oxidase Inhibitors&#xD;
&#xD;
               2. Sympathomimetics or methadone&#xD;
&#xD;
               3. Antipsychotic agents&#xD;
&#xD;
               4. Modafinil&#xD;
&#xD;
          -  The following medications are permitted if the dose has been stable for ≥ 28 days&#xD;
&#xD;
               1. Short acting benzodiazepines, qhs administration only&#xD;
&#xD;
               2. Anticonvulsants, including gabapentin and pregabalin&#xD;
&#xD;
               3. Bupropion&#xD;
&#xD;
               4. Tricyclic Antidepressants&#xD;
&#xD;
               5. Anti-spasmodics such as baclofen or tizanidine&#xD;
&#xD;
               6. Anticholinergic medication&#xD;
&#xD;
               7. Selective serotonin(-norepinephrine) reuptake inhibitors&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>59 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Sarah A Morrow, MD, MS, FRCPC</last_name>
    <role>Principal Investigator</role>
    <affiliation>London Health Sciences Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>London Health Sciences Center and St. Joseph's Heathcare Center (Parkwood)</name>
      <address>
        <city>London</city>
        <state>Ontario</state>
        <zip>N6G 1W8</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <verification_date>May 2015</verification_date>
  <study_first_submitted>August 13, 2012</study_first_submitted>
  <study_first_submitted_qc>August 16, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 17, 2012</study_first_posted>
  <last_update_submitted>May 7, 2015</last_update_submitted>
  <last_update_submitted_qc>May 7, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 12, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>London Health Sciences Centre</investigator_affiliation>
    <investigator_full_name>Sarah Morrow</investigator_full_name>
    <investigator_title>Assistant Professor of Neurology</investigator_title>
  </responsible_party>
  <keyword>Cognitive Impairment</keyword>
  <keyword>Multiple Sclerosis</keyword>
  <keyword>Processing Speed</keyword>
  <keyword>Treatment</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Multiple Sclerosis</mesh_term>
    <mesh_term>Sclerosis</mesh_term>
    <mesh_term>Cognitive Dysfunction</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Adderall</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

